NASDAQ:PLSE - Pulse Biosciences Stock Price, Forecast & News

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PLSE stock has increased by 5.0% and is now trading at $6.68. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pulse Biosciences.

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Pulse Biosciences.

Pulse Biosciences Inc (NASDAQ:PLSE) announced its quarterly earnings results on Monday, March, 16th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.05. View Pulse Biosciences' earnings history.

1 Wall Street analysts have issued 12 month price targets for Pulse Biosciences' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Pulse Biosciences' stock price to reach $6.00 in the next twelve months. This suggests that the stock has a possible downside of 10.2%. View analysts' price targets for Pulse Biosciences.

Media stories about PLSE stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulse Biosciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutPulse Biosciences.

Pulse Biosciences saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,610,000 shares, an increase of 11.5% from the February 13th total of 2,340,000 shares. Based on an average daily trading volume, of 79,800 shares, the days-to-cover ratio is presently 32.7 days. Currently, 23.5% of the company's shares are sold short. View Pulse Biosciences' Current Options Chain.

Some companies that are related to Pulse Biosciences include Orthofix Medical (OFIX), OraSure Technologies (OSUR), LeMaitre Vascular (LMAT), SurModics (SRDX), MiMedx Group (MDXG), Anika Therapeutics (ANIK), Intersect ENT (XENT), AngioDynamics (ANGO), Antares Pharma (ATRS), Vapotherm (VAPO), Repro Med Systems (KRMD), SI-Bone (SIBN), Repro-Med Systems (REPR), Utah Medical Products (UTMD) and GenMark Diagnostics (GNMK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Energous (WATT), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), AbbVie (ABBV), Fate Therapeutics (FATE), Portola Pharmaceuticals (PTLA), Roku (ROKU) and Exelixis (EXEL).

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (0.92%), Geode Capital Management LLC (0.75%), Griffin Asset Management Inc. (0.24%), Bank of New York Mellon Corp (0.15%), UBS Group AG (0.07%) and Barclays PLC (0.05%). View institutional ownership trends for Pulse Biosciences.

PLSE stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. View insider buying and selling activity for Pulse Biosciences.

PLSE stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Barclays PLC, Geode Capital Management LLC, Griffin Asset Management Inc., UBS Group AG, Bank of New York Mellon Corp, and Citigroup Inc.. View insider buying and selling activity for Pulse Biosciences.

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PLSE stock can currently be purchased for approximately $6.68.

Pulse Biosciences has a market capitalization of $139.14 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe. View additional information about Pulse Biosciences.

The official website for Pulse Biosciences is http://www.pulsebiosciences.com/.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]